The Wharton Moneyball Post Game Podcast


Wharton Moneyball: Changes to the Atlantic League & Predictive Analytics

Ep. 160

Show from 7/24/19

In this episode of Wharton Moneyball, as the Major League Baseball Trade Deadline approaches teams will begin to become buyers or sellers. Tune in to hear what the data says about the worth of a few months of a rental player vs a handful of lesser known prospects. Then Hosts Cade Massey, Eric Bradlow, Adi Wyner and Shane Jensen dive into this weekend’s British Open and discuss what you should be watching as NFL training camps open. Plus find out what rule changes the Atlantic League is undergoing and hear about the tech they're using including robot umpires!


Ron Yurko - PhD student in the Department of Statistics & Data Science at Carnegie Mellon University. His research there mainly focuses on developing statistical methodology oriented towards applications in genetics and genomics. He also publishes research on statistics in sports, and has developed multiple R packages to enable easy access of publicly available data.

Follow him on Twitter: @Stat_Ron

Check out his research here:

Rick White - President of the Atlantic League, which this year is undergoing some massive rule changes and really altering the way the game is played. Prior to his time as President, Rick worked as an executive for MLB as well as with companies including Nike. The league started 1998 and prides itself on being the most innovative league in professional baseball, offering the highest level of minor league baseball playing skills, and being a player gateway to Major League Baseball.

More information on their website:

More Episodes


7/22/2020: COVID-19, Sports, David Fajgenbaum

David Fajgenbaum, MD, MBA, MSc is a groundbreaking physician-scientist, disease hunter, and bestselling author of the acclaimed memoir, Chasing My Cure: A Doctor's Race to Turn Hope Into Action. Fajgenbaum went from being a beast-like college Quarterback to receiving his last rites while in medical school and nearly dying four more times battling Castleman disease. To try to save his own life, he spearheaded an innovative approach to research and discovered a possible treatment that has put him into an extended remission. Now, he is spreading this approach to advance cures for other diseases and sharing lessons he learned about living from nearly dying through Chasing My Cure.One of the youngest individuals ever appointed to the faculty at Penn Medicine and the top 1 percent youngest grant awardees of a leading NIH grant, Dr. Fajgenbaum is co-founder and executive director of the Castleman Disease Collaborative Network (CDCN) and Associate Director, Patient Impact, for the Penn Orphan Disease Center. He has been recognized on the Forbes 30 Under 30 list, as a top healthcare leader by Becker's Hospital Review, the Global Genes RARE Champion of Hope: Science awardee, and one of three recipients--including Vice President Joe Biden--of a 2016 Atlas Award from the World Affairs Council of Philadelphia. Before co-founding the CDCN, Dr. Fajgenbaum co-founded and led the Actively Moving Forward Support Network, a non-profit organization dedicated to supporting grieving college students. Dr. Fajgenbaum has been profiled in a cover story by The New York Times as well as by Good Morning America, CNN, and the Today Show, among others.Dr. Fajgenbaum earned a BS from Georgetown University magna cum laude with honors and distinction, MSc from the University of Oxford, MD from the University of Pennsylvania Medical School, and MBA from The Wharton School. He is a former Division I college quarterback, state-champion weight lifter, and co-founder of a national grief support network.